Objective-The sensitivity of platelets to aggregating agents increases when low-density lipoprotein (LDL) binds to apolipoprotein E receptor 2Ј (apoER2Ј), triggering activation of p38 MAPK and formation of thromboxane A 2 . LDL signaling is terminated by PECAM-1 through recruitment and activation of the Ser/Thr protein phosphatase PP2A, but platelets remain unresponsive to LDL when PECAM-1 activation disappears. We report a second mechanism that halts LDL signaling and in addition lowers platelet responsiveness to aggregating agents. Methods and Results-After a first stimulation with LDL, platelets remain unresponsive to LDL for 60 minutes, despite normal apoER2Ј activation by a second dose of LDL. A possible cause is persistent activation of the tyrosine phosphatases SHP-1 and SHP-2, which may not only block a second activation of p38 MAPK , PECAM-1, and PP2A by LDL but also seem to reduce aggregation by TRAP, collagen, and ADP. Conclusion-These findings reveal that p38 MAPK phosphorylation and platelet activation by LDL are suppressed by two mechanisms: (1) short activation of PECAM-1/PP2A, and (2) prolonged activation of SHP-1 and SHP-2. Activation of SHP-1 and SHP-2 is accompanied by reduced responsiveness to aggregating agents, which-if present in vivo-would make LDL an aggregation inhibitor during prolonged contact with platelets. (Arterioscler Thromb Vasc Biol. 2009;29:372-379.) 
the risk for cardiovascular disease (CVD). 1 Platelets are key elements in the development of arterial thrombosis and are activated by LDL. At physiological concentrations (1 g protein/L), LDL fails to induce platelet aggregation and secretion but significantly enhances responses initiated by thrombin, collagen, and ADP. 2 The process of sensitization by LDL takes 5 minutes, reflecting the time required to prime platelets to aggregating agents. We recently identified apolipoprotein E receptor 2Ј (apoER2Ј), a splice variant of the LDL-receptor family member apoER2, as the platelet LDLreceptor. 3 Evidence was based on (1) blockade of LDLsignaling by receptor-associated protein, which inhibits ligand binding to LDL-receptor family members, (2) colocalization of LDL and apoER2Ј on the platelet surface, (3) similar platelet activation by LDL and an antiapoER2 antibody, and (4) tyrosine phosphorylation of apoER2Ј through the Src family member Fgr on LDL binding. LDL activates apoER2Ј through a specific domain in apolipoprotein B100 (apoB100) known as the B-site (amino acids 3359 RLTRKRGLKLA 3369 ) 4 and initiates signaling to the Ser/ Thr kinase p38 mitogen-activated protein kinase (p38 MAPK ) through dual phosphorylation of Thr-180 and Tyr-182. 3, 5, 6 Phosphorylated p38 MAPK activates cytosolic phospholipase A 2 (cPLA 2 ), which releases arachidonic acid from membrane phospholipids for formation of thromboxane A 2 (TxA 2 ), a potent platelet activator. 5, 7, 8 Together with signals triggered by a second agonist, TxA 2 synergistically activates integrin ␣ IIb ␤ 3 , inducing fibrinogen binding and further activation through outside-in signaling. 9 LDL-signaling through p38 MAPK is terminated by platelet endothelial cell adhesion molecule-1 (PECAM-1), a 130-kDa transmembrane glycoprotein of the immunoglobulin superfamily of cell adhesion molecules expressed in hematopoietic and vascular cell types. 10 PECAM-1 inhibits aggregation by collagen in vitro 11, 12 and thrombus formation in vivo as shown by the faster formation of stable thrombi in PECAM-1-deficient mice compared with controls. 13 PECAM-1 consists of 6 extracellular IgG-like homology domains, a transmembrane domain, and a cytoplasmic tail with 2 immunoreceptor Tyrbased inhibitory motifs (ITIMs) 14, 15 with the consensus sequence L/I/V/S-x-Y-x-x-L/V, which is characteristic for inhibitory receptors. 16 -18 Phosphorylation of the ITIMs induces recruitment and activation of the Src homology 2 (SH2) domain-containing protein phosphatase 2A (PP2A), which through inhibition of p38 MAPK terminates LDL signaling to TxA 2 . 19 Indeed, the PP2A inhibitor okadaic acid changes the transient LDL activation of p38 MAPK into a strong and persistent signal. 19 PP2A is a ubiquitously expressed type II protein Ser/Thr phosphatase that consists of an active core dimer composed of a catalytic subunit and a scaffold protein, which mediates interaction with two regulatory subunits. Actions of PP2A vary from suppression of tumor growth to maintenance of cell viability. 20 In addition to PP2A, phosphorylated ITIMs on PECAM-1 activate the SH2 domain-containing tyrosine phosphatases-1 (SHP-1) and -2 (SHP-2). [21] [22] [23] [24] SHP-1 and SHP-2 are structurally similar and consist of two N-terminal tandem SH2 domains linked to a C-terminal catalytic phosphatase domain with two tyrosine phosphorylation sites. Phosphorylation of SHP-1 and SHP-2 introduces docking sites for adaptor molecules like growth factor receptor-bound protein-2 (Grb2) regulating further signaling to integrin ␣ IIb ␤ 3 . 25 Despite their structural similarity, the expression patterns and functions of SHP-1 and SHP-2 differ. SHP-1 is mainly expressed in hematopoietic cells where it suppresses cell activation by growth factors, cytokines, and integrins. 26 In contrast, SHP-2 is ubiquitously expressed and functions as a positive regulator of cytokine and growth factor signaling. 27 However, SHP-2 may also participate in inhibitory pathways such as those initiated by ITIM-bearing receptors, which are significantly reduced in SHP-2-deficient DT40 chicken B cells. 23 SHP-1 and SHP-2 interfere with collagen-induced platelet responsiveness by terminating the activation of p38 MAPK as shown in studies with the tyrosine phosphatase inhibitor phenylarsine oxide. 28 Because the activation of p38 MAPK by LDL-bound apoER2Ј is terminated by active PECAM-1 and PP2A within 10 minutes, 19 one would expect that platelets restore their sensitivity to LDL. Here, we show that after termination of LDL signaling by PECAM-1 and PP2A, a period follows in which platelets remain resistant against activation by LDL through the combined action of SHP-1 and SHP-2. This mechanism also reduces responsiveness to aggregating agents which, if present in vivo, would make LDL an aggregation inhibitor during prolonged platelet contact.
Methods
To elucidate mechanisms that make platelets unresponsive to LDL, human platelets were treated with 2 doses of LDL (1 g protein/L) with a 30-minute, and in one experiment 60-minute, interval (37°C). Activation of apoER2Ј, p38 MAPK , PECAM-1, PP2A, SHP-1, and SHP-2 was inferred from their phosphorylations detected by Western blotting. Functional consequences were determined by aggregation experiments in response to TRAP, collagen, and ADP. A full description of these methods is available in the Methods section of the online supplement (available at http://atvb.ahajournals.org).
Results

Loss of Platelet Sensitization by LDL
Pretreatment of platelets with 1 g/L LDL for 5 minutes enhanced platelet aggregation induced by TRAP, collagen, and ADP by 54%, 29%, and 89%, respectively, as a result of LDL-signaling to p38 MAPK and TxA 2 (supplemental Figure I , and earlier work 3, 5 ). Especially the effect of LDL on ADP-induced aggregation illustrates the increase in secondary aggregation by upregulation of TxA 2 formation. We showed previously that LDL signaling was terminated by PECAM-1 through recruitment and activation of the Ser/Thr phosphatase PP2A and that within 10 minutes p38 MAPK , PECAM-1, and PP2A had returned to the inactive state observed before platelet-LDL contact. 19 To investigate whether the sensitivity to LDL was restored thereafter, platelets were treated with LDL for 30 minutes to induce a first phase of LDL-induced signals and subsequently incubated with a second dose of LDL. A second addition of LDL failed to enhance aggregation by TRAP, collagen, and ADP (not shown). Instead, these platelet-aggregating agents induced much weaker responses in suspensions treated with LDL for 30 minutes than in concurrently run controls ( Figure 1A through 1D). Similar results were found after treatment with the B-site peptide, which resembles the receptor-specific binding domain within apoB100 ( Figure 1A ). PAC-1 binding experiments support these observations: TRAP-induced PAC-1 binding was reduced by 52% after prolonged platelet-LDL contact (data not shown). A likely cause for loss of LDL responsiveness is desensitization of apoER2Ј, the receptor through which LDL activates platelets. To address this possibility, tyrosine phosphorylation of apoER2Ј was determined after a first and second contact with LDL. Both additions induced a rapid and transient apoER2Ј tyrosine phosphorylation, indicating that loss of responsiveness to LDL was not caused by loss of signaling through apoER2Ј (Figure 2A) . In contrast, a second stimulation by LDL failed to trigger a second activation of p38 MAPK ( Figure 2B ). As a consequence, platelets lost their capacity to form TxA 2 (insert Figure 2B ). Apparently, on first contact of platelets with LDL, a mechanism is initiated that interferes with apoER2Ј-signaling to p38 MAPK and in addition inhibits agonist-induced platelet aggregation.
Prolonged Platelet-LDL Contact Blocks PECAM-1 and PP2A Activation
P38 MAPK activation by LDL contact is downregulated by PECAM-1 and PP2A. 19 Because this property makes these proteins likely candidates for persistant suppression of p38 MAPK , their activation was measured after a first and second treatment with LDL. A first addition confirmed the rapid and reversible activation of PECAM-1 and PP2A observed in earlier studies, 19 but a second stimulation by LDL failed to induce significant stimulation of PECAM-1 and PP2A (supplemental Figure II) . Thus, the mechanism that inhibits apoER2Ј-signaling to p38 MAPK after prolonged contact with LDL probably also abolishes apoER2Ј-signaling to PECAM-1 and PP2A.
SHP-1 and SHP-2 Prevent Recovery of LDL Sensitization After a First Contact With LDL
Activated PECAM-1 is known to recruit the tyrosine phosphatases SHP-1 and SHP-2, albeit with different affinities. 24 To investigate whether SHP-1 and SHP-2 caused the loss of apoER2Ј-signaling to p38 MAPK , PECAM-1, and PP2A, tyrosine phosphorylation of these phosphatases was measured. A first stimulation triggered an immediate rise in tyrosine phosphorylated SHP-1 ( Figure 3A ) and SHP-2 ( Figure 3B ). Importantly, the fast dephosphorylation observed for
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PECAM-1 was absent in SHP-1 and SHP-2, and it took 60 (SHP-2) to 120 minutes (SHP-1) before their tyrosine phosphorylation returned to prestimulation values ( Figure 3C ). After 30 minutes platelet-LDL contact, approximately 50% of SHP-1 and SHP-2 were still in the activated state, which is the period in which LDL signaling through apoER2Ј to p38 MAPK , PECAM-1, and PP2A were blocked and aggregation by TRAP, collagen, and ADP was suppressed. A second LDL addition induced an immediate increase in tyrosine phosphorylated SHP-1 and SHP-2, indicating that apoER2Јsignaling to these phosphatases had remained intact. These findings suggest that active SHP-1 and SHP-2 inhibit apoER2Ј-mediated signaling to p38 MAPK , PECAM-1, and PP2A. Apparently, this mechanism also interferes with platelet aggregation induced by TRAP, collagen, and ADP.
To investigate the relation between p38 MAPK inhibition and activation of SHP-1 and SHP-2 in more detail, platelets were stimulated with LDL for 1 minute to induce maximal phosphorylation of p38 MAPK , and phosphorylated p38 MAPK was immunoprecipitated. After SDS-PAGE and Western blotting, membranes were probed with antibodies against phosphorylated p38 MAPK , PECAM-1, SHP-1, and SHP-2 ( Figure 4A ). Immunoprecipitates were devoid of PECAM-1 but did contain SHP-1 and SHP-2. Thus, after 1 minute of incubation with LDL, SHP-1 and SHP-2 associated with p38 MAPK , thereby probably causing its dephosphorylation. Because p38 MAPK dephosphorylation was completed within 5 minutes, one would expect a similar rapid disappearance of the complex. However, immunoprecipitation of SHP-2 and Western blotting for p38 MAPK showed that the complex remained intact for at least 30 minutes, which is well after the disappearance of phosphorylated p38 MAPK ( Figure 4B ). Similar results were found for SHP-1 and p38 MAPK (data not shown). These data indicate that apoER2Ј-mediated signaling to p38 MAPK is under control of SHP-1 and SHP-2.
An immunoprecipitation of SHP-2 followed by Western blotting for p38 MAPK revealed already a slight association of the 2 proteins before LDL was added. To investigate whether this was caused by platelet activation before the start of the incubations, studies were repeated with platelets collected and prepared in the presence of iloprost to induce metabolic arrest. The association remained present raising the possibility that in circulating platelets part of p38 MAPK undergoes persistant inactivation through binding to SHP-2 ( Figure 4C ). This would imply that the removal of platelets from the LDL-containing plasma during platelet isolation and resuspension in buffer would relieve this inhibition. To investigate this possibility, washed platelets from a subject with normal LDL (1.10 g apoB/L) and from a subject with familial hypercholesterolemia (FH; 1.87 g apoB/L) were resuspended in buffer without and with subsequent reconstitution with LDL to apoBlevels characteristic for the two individuals. After correction for the decline in platelet reactivity inherent to platelet storage for long periods, there was a slight but consistent recovery in LDL-free medium, especially in platelets from the FH donor (for details, please see supplemental Figure III ).
Recovery of Platelet Inhibition by LDL
To confirm that the dissociation of the SHP1/2-p38 MAPK complex restored stimulation of platelet aggregation by LDL, platelets were incubated with LDL for 60 minutes and stimulated with TRAP. Aggregations were slightly reduced compared to controls incubated with buffer, but a second addition of LDL strongly enhanced TRAP-induced aggregation ( Figure 5A ). Recovery of aggregation was accompanied by recovery of LDL-induced TxA 2 formation ( Figure 5B) . Apparently, the disappearance of the SHP1/2-p38 MAPK complex followed by deactivation of these phosphatases restored platelet stimulation by LDL.
Discussion
When LDL binds to platelet apoER2Ј, three signaling pathways are initiated that start activating, inhibiting, and desensitizing mechanisms and together tightly regulate platelet responsiveness to LDL and probably other apoB100-containing lipoproteins. A first response is the activation of p38 MAPK resulting in the cPLA 2 -mediated release of arachidonic acid and formation of TxA 2 , 5,8,29 a potent activating agent that enhances platelet aggregation initiated by TRAP, collagen, and ADP (supplemental Figure IV, step a) . Optimal priming by LDL requires 5 minutes reflecting the time required to synthesize a sufficient amount of TxA 2 to facilitate platelet aggregation. Persistent TxA 2 formation would eventually make LDL an independent platelet aggregating agent which would be incompatible with life. Thus, a second mechanism that halts TxA 2 formation is required to prevent overstimulation. This mechanism is the Fgr-mediated activation of PECAM-1 and recruitment of PP2A, which turn off signaling through the p38 MAPK pathway within about Figure 2 . Blockade of apoER2Ј-signaling to p38 MAPK after prolonged platelet-LDL contact. A, Platelets were incubated with a first dose of LDL followed by a second dose 30 minutes later. ApoER2Ј was immunoprecipitated and tyrosine phosphorylation was detected. Alpha-actinin was detected as a control for equal lane loading. B, Platelets were incubated as described under A and phosphorylated and total p38 MAPK were detected. Phosphorylation after 1 minute stimulation with LDLϭ100%. Inset, TxA 2 formation during the first 5 minutes after addition of LDL before and after 30 minutes incubation with LDL. (meansϮSEM, nϭ3).
10 minutes of platelet-LDL contact 19 (supplemental Figure  IV, step b) . The present study reveals a third mechanism that makes platelets unresponsive to LDL for 60 minutes and involves SHP-1 and SHP-2 (supplemental Figure IV,  steps b and c) .
Earlier studies in collagen-stimulated platelets revealed an inhibitory role for PP2A as well as SHP-1 and SHP-2, 28 and the present data extend these observations to LDLsignaling. SHP-1 and SHP-2 are tyrosine phosphorylated on binding of their SH2 domains to the ITIM motifs in activated PECAM-1. 21, 22, 24, 30, 31 PECAM-1, SHP-1, and SHP-2 are all activated within minutes of platelet-LDL contact, which fits with the concept that PECAM-1 activates SHP-1 and SHP-2. Activated SHP-1 and SHP-2 associate with phosphorylated p38 MAPK , illustrating an activation-specific downregulation of the pathway signaling to TxA 2 (supplemental Figure IV,  step 1 ). Additionally, a small but persistent association between p38 MAPK and SHP-2 was present before platelet stimulation, suggesting that in circulating platelets a part of p38 MAPK is persistently inactivated through binding to SHP-2. PECAM-1 is absent in immunoprecipitates of phosphorylated p38 MAPK , suggesting that after recruitment by PECAM-1, SHP-1 and SHP-2 subsequently bind and dephosphorylate p38 MAPK . The prolonged activation of SHP-1 and SHP-2 not only prevents a second activation of p38 MAPK but also blocks signaling from apoER2Ј to PECAM-1 and PP2A (supplemental Figure IV, step 2) , without interfering with receptor activation (Figure IV, step 3) . A plausible explanation is that the Src-and Csk-related kinases that mediate PECAM-1 activation [32] [33] [34] are under control of SHP-1 and SHP-2. 19 Addition of a second dose of LDL to platelets after prior contact with LDL for 30 minutes induced upregulation of active SHP-1 and SHP-2 under conditions that PECAM-1 was inactive. Thus, apart from the PECAM-1-mediated activation of SHP-1 and SHP-2, these phosphatases can be activated by a PECAM-1-independent mechanism (supplemental Figure IV , steps b and c, respectively). In addition to PECAM-1, many other ITIM-bearing receptors are known to recruit SHP-1 or SHP-2, including the collagen receptor leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1), CD22, CD72 (Sema 4D), TREM-like transcript-1 (TLT-1), 35 G6b-B, 36 the inhibitory macrophage receptor Signal Regulatory Protein (SIRP) ␣, killer immunoglobulin-like receptor (KIR), immunoglobulin-like transcripts (ILT), and the T-cell antigen Ly49. Platelets express the ITIM-containing receptors CD72, 37 TLT-1, 35 and G6b. 36 CD72 is a type II integral membrane protein, and tyrosine phosphorylation of its ITIM motifs recruit SHP-1. In resting platelets, CD72 is associated with SHP-1, suggesting a role for the complex in preserving the dormant state. 38 TLT-1 is a triggering receptor expressed on myeloid (TREM) family member and is expressed in ␣-granules. 35 Platelet activation induces surface expression and recruitment of SHP-1 39 and SHP-2. 40 TLT-1 has therefore the potential to inhibit platelet functions but enhances rather than attenuates Ca 2ϩ signaling. 40 G6b is a member of the immunoglobulin superfamily and consists of multiple isoforms. Only G6b-B has ITIM motifs that when tyrosine phosphorylated, bind SHP-1 and SHP-2. 41 Cross-linking of G6b-B prior to platelet activation leads to a significant inhibition of aggregation. 36 Further research is required to elucidate which receptor is responsible for the PECAM-1-independent activation of SHP-1 and SHP-2.
The blockade of apoER2Ј-mediated activation of p38 MAPK by SHP-1 and SHP-2 explains why priming of platelets to aggregating agents by a second dose of LDL disappears. Interestingly, this property also attenuates platelet aggregation in the absence of a second dose of LDL. Aggregations induced by TRAP, collagen, and ADP are known to be facilitated by TxA 2 formation and positive feedback activation of the mechanisms that execute aggregation and secretion. The diminished aggregation by platelets with active SHP-1 and SHP-2 is caused by inhibition of p38 MAPKmediated TxA 2 formation. This is particularly evident in aggregation induced by ADP, where the second aggregation phase is absent in platelets with active SHP-1 and SHP-2. After about 60 minutes (SHP-2) to 120 minutes (SHP-1), the phosphatases regained the inactive conformation seen before LDL contact. This led to recovery of LDL-induced TxA 2 formation and enhancement of TRAP-aggregation illustrating the reversible nature of platelet inhibition through SHP1 and SHP-2.
Analysis of the kinetics of SHP-1 and SHP-2 activation by LDL did not reveal major differences. SHP-2 might be the preferred phosphatase in PECAM-1 signaling because the phosphorylated ITIMs bind SHP-2 with higher affinity than SHP-1. 24 Further studies are required to determine whether SHP-1 and SHP-2 have a similar role in the dephosphorylation of p38 MAPK and the loss of responsiveness of platelets to agonists.
Loss of a normal lipoprotein profile is a prominent risk factor for CVD. Both abnormalities in steady state levels in fasting individuals and in changes after a meal correlate with CVD risk. Under preprandial conditions, high levels of apoB-containing lipoproteins like LDL make individuals prone to CVD. Under postprandial conditions, levels of apoB-containing lipoproteins increase, [42] [43] [44] and variations in subclasses of these lipoproteins are even greater when lipoprotein lipase is associated to apoB. 45 The rapid postprandial increase in triglyceride-rich lipoproteins (containing apoB100 and apoE) of normal individuals is increased in diseases related to arterial disease eg, diabetes mellitus, 46 and myocardial infarction. 47 Together, these observations illustrate that circulating platelets encounter major fluctuations in concentrations of apoB-containing lipoproteins. The mechanisms that suppress platelet activation through PECAM-1/ PP2A and SHP-1 and SHP-2 might therefore be important contributors to the reduction of CVD risk. The possibility that circulating platelets suppress the p38 MAPK pathway through constitutive interaction with SHP-1 and SHP-2 is an intriguing subject for further research.
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